ReviewThe Journal of molecular diagnostics : JMD2011
Molecular methods and platforms for infectious diseases testing a review of FDA-approved and cleared assays.
Review in The Journal of molecular diagnostics : JMD, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed.
- Article
- Rapid Amplification and Detection of Single-Stranded Nucleic Acids for Point-of-Care Diagnosis.Small methods · 2025Review
- FDA's proposed rule and its regulatory impact on emerging and reemerging neglected tropical diseases in the United States.PLoS neglected tropical diseases · 2024Review
- Bioluminescent Intercalating Dyes for Ratiometric Nucleic Acid Detection.ACS chemical biology · 2024Article
- S9.6-based hybrid capture immunoassay for pathogen detection.Scientific reports · 2023Article
- CRISPR‑based diagnostic approaches: Implications for rapid management of future pandemics (Review).Molecular medicine reports · 2023Review
- Simplified Cas13-based assays for the fast identification of SARS-CoV-2 and its variants.Nature biomedical engineering · 2022Article
- SARS-CoV-2 Continuous Genetic Divergence and Changes in Multiplex RT-PCR Detection Pattern on Positive Retesting Median 150 Days after Initial Infection.International journal of molecular sciences · 2022Article
- RT-qPCR Diagnostics: The "Drosten" SARS-CoV-2 Assay Paradigm.International journal of molecular sciences · 2021Article
- HIV-1 Drug Resistance Genotyping in Resource Limited Settings: Current and Future Perspectives in Sequencing Technologies.Viruses · 2021Article
- Consolidating and Upscaling Molecular Research Capacity in Nigeria: On Who's Account?Frontiers in research metrics and analytics · 2021Review
- Implementation and Validation of the Roche Light Cycler 480 96-Well Plate Platform as a Real-Time PCR Assay for the Quantitative Detection of Cytomegalovirus (CMV) in Clinical Specimens Using the Luminex MultiCode ASRs System.Medical sciences (Basel, Switzerland) · 2020Article
- Appropriate Use and Future Directions of Molecular Diagnostic Testing.Current infectious disease reports · 2020Review
- Article
- Peptides for Infectious Diseases: From Probe Design to Diagnostic Microarrays.Antibodies (Basel, Switzerland) · 2019Review
- Memory CD4Genes and immunity · 2019Article
- Synthesis of comb-shaped DNA using a non-nucleosidic branching phosphoramidite.Organic & biomolecular chemistry · 2018Article
- Article
- Strategies for Optimizing the Diagnostic Predictive Value of Clostridium difficile Molecular Diagnostics.Journal of clinical microbiology · 2017Article
- Nucleic acid detection with CRISPR-Cas13a/C2c2.Science (New York, N.Y.) · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The superior sensitivity and specificity associated with the use of molecular assays has greatly improved the field of infectious disease diagnostics by providing clinicians with results that are both accurate and rapidly obtained. Herein, we review molecularly based infectious disease diagnostic tests that are Food and Drug Administration approved or cleared and commercially available in the United States as of December 31, 2010. We describe specific assays and their performance, as stated in the Food and Drug Administration's Summary of Safety and Effectiveness Data or the Office of In Vitro Diagnostic Device Evaluation and Safety's decision summaries, product inserts, or peer-reviewed literature. We summarize indications for testing, limitations, and challenges related to implementation in a clinical laboratory setting for a wide variety of common pathogens. The information presented in this review will be particularly useful for laboratories that plan to implement or expand their molecular offerings in the near term.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.